<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03452605</url>
  </required_header>
  <id_info>
    <org_study_id>T1DCFMRI</org_study_id>
    <nct_id>NCT03452605</nct_id>
  </id_info>
  <brief_title>The Effect of Cocoa Flavanol on the BOLD Response and Cognitive Function in Type 1 Diabetes</brief_title>
  <official_title>Effect of Acute Cocoa Flavanol Intake on the BOLD Response and Cognitive Function in Patients With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vrije Universiteit Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vrije Universiteit Brussel</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 1 Diabetes (T1D) is associated with microvascular changes in the brain, which can cause
      cognitive dysfunction. Cocoa flavanols (CF) can stimulate vasodilation, resulting in enhanced
      cerebral blood flow and better cognitive function. This study aimed to investigate whether
      acute CF supplementation can improve cognitive function and the hemodynamic (BOLD) response
      in T1D patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 20, 2015</start_date>
  <completion_date type="Actual">March 15, 2017</completion_date>
  <primary_completion_date type="Actual">March 15, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cognitive function</measure>
    <time_frame>5 min</time_frame>
    <description>reaction time (milliseconds) on the flanker task</description>
  </primary_outcome>
  <primary_outcome>
    <measure>BOLD fmri response</measure>
    <time_frame>5 min</time_frame>
    <description>blood oxygenation level dependent response during flanker test</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>high cocoa flavanol drink</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high cocoa flavanol drink (900 mg cocoa flavanol dissolved in 300 ml skimmed milk) 2h pre-fMRI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low cocoa flavanol drink</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>low cocoa flavanol drink (30 mg cocoa flavanol dissolved in 300 ml skimmed milk), matched for theobromine, caffeine and macronutrients with the high cocoa flavanol drink 2h-pre fMRI</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>cocoa flavanol supplementation</intervention_name>
    <description>cocoa flavanols (containing 196 mg epicatechin)</description>
    <arm_group_label>high cocoa flavanol drink</arm_group_label>
    <arm_group_label>low cocoa flavanol drink</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  non-smoking T1D patients or matched healthy controls

          -  having diabetes for more than 1 year

          -  males and females older than 18 years

          -  stable medications for more than 6 months (no use of cholinesterase inhibitors or
             prior use of multivitamins was allowed)

          -  adequate visual and auditory acuity to allow neuropsychological testing.

        Exclusion Criteria:

          -  participant enrolled in any investigational drug study within 2 months or longer,
             depending on the investigational drug half-life

          -  history in the past 2 years of epileptic seizures or any major psychiatric disorder

          -  history or MRI evidence of brain damage, including significant trauma, stroke,
             hydrocephalus, mental retardation, or serious neurological disorder,

          -  significant history of alcoholism or drug abuse

          -  unstable cardiac, renal, lung, liver, or other severe chronic disease

          -  hypertension (systolic blood pressure ≥160 mmHg, diastolic blood pres-sure ≥100 mmHg)
             or hypotension (systolic blood pressure &lt;100 mmHg)

          -  pacemaker or other medical metal devices that precludes performing MRI,

          -  chronic inflammatory diseases, including lupus, rheumatoid arthritis, or polymyalgia
             rheumatic

          -  macrovascular complications

          -  retinopathy, nephropathy or neuropathy (microvascular complications)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2018</study_first_submitted>
  <study_first_submitted_qc>March 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2018</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vrije Universiteit Brussel</investigator_affiliation>
    <investigator_full_name>Romain Meeusen</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

